Assessing Treatment Response with FcRn-Targeted Therapy

In ‘Assessing Treatment Response with FcRn-Targeted Therapy in MG,’ our panel explores how clinicians determine whether an FcRn-targeted therapy is providing an adequate response. Faculty note that FcRn therapies can produce improvement relatively quickly, with responses observed within the first treatment cycle in clinical studies, but emphasize that the time needed to determine the full depth of response can vary. Some patients may continue to improve over repeated cycles, making the decision to continue or change treatment dependent on both objective improvement and the individual patient's expectations.

The experts discuss several ways to assess response, including MG-ADL and simple patient-centered questions about whether the current level of symptom control would be acceptable if maintained. They emphasize that adequate response is not static; patient expectations may change as disease improves and previously accepted limitations become less acceptable.

Corticosteroid reduction emerges as a major component of treatment success. Faculty describe the long-term toxicities associated with corticosteroids and discuss goals for reducing prednisone exposure once adequate control is established. The panel considers whether persistent steroid dependence should prompt additional therapeutic optimization even when MG symptoms have improved. They also acknowledge that the appropriate target dose depends on disease severity and comorbidities, while generally favoring the lowest feasible chronic exposure. Overall, treatment success is framed as achieving meaningful and durable disease control while simultaneously minimizing the long-term burden of therapy.

Our next episode, ‘Individualizing FcRn-Targeted Therapy and Earlier Treatment in MG,’ will explore how patient-defined priorities, comorbidities, access, and disease severity influence shared decision-making and consideration of FcRn therapy earlier in the treatment course.